Earning approval to use a new cardiovascular drug in the clinical setting can cost 100+ times the average of bringing other medications to market.  

A former Kentucky cardiologist received five years of prison time May 2 after allegedly performing numerous unnecessary heart procedures as part of a healthcare fraud scheme.

The American Heart Association, alongside the American Cancer Society Cancer Action Network, American Lung Association, American Academy of Pediatrics and Tobacco-Free Kids, is throwing its support behind federal efforts to raise the tobacco sale age to 21 nationwide.

Heart disease might be the leading cause of death in the United States, but, according to a recent report, it’s also one of the least searched-for diseases on the internet.

The FDA has expanded Praluent’s (alirocumab) regulatory approval to reflect the reduced risk of heart attack, stroke and unstable angina evidenced in 2018’s ODYSSEY OUTCOMES trial—a move announced the same day drugmaker Sanofi released its first-quarter earnings, which were lower than expected.

CMS saw an influx of public commentary after it first published a draft of recommendations for revising the United States’ national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) more than a month ago. Now that the 30-day comment period is over, the agency has a decision to make.

The global wearable medical devices market is expected to surpass $29 billion by 2026, according to a report from Transparency Market Research (TMR), expanding at a projected compound annual growth rate (CAGR) of more than 17% over the next seven years.

The CDC’s most recent Health, United States report, released this April, reveals the extent to which racial and ethnic disparities in the U.S. affect cardiovascular care and rates of heart disease in the country.